Erratum: Pioglitazone, a PPARg Agonist, Suppresses CYP19 Transcription: Evidence for Involvement of 15-Hydroxyprostaglandin Dehydrogenase and BRCA1 (Cancer Prev Res (2012) 5 (1183–1194) DOI: 10.1158/1940-6207.CAPR-12-0201)

Kotha Subbaramaiah, Louise R. Howe, Xi Kathy Zhou, Peiying Yang, Clifford A. Hudis, Levy Kopelovich, Andrew J. Dannenberg

Research output: Contribution to journalComment/debatepeer-review

Abstract

This article (1) has been retracted at the request of the authors. There was evidence of data falsification or fabrication found in two figures. Suspicious duplications of band images were found in Fig. 2 and Fig. 4E. A copy of this Retraction Notice was sent to the last known e-mail addresses for the 7 authors. All authors agreed to the retraction. The authors apologize to the scientific community and deeply regret any inconveniences or challenges resulting from the publication and subsequent retraction of this article.

Original languageEnglish (US)
Pages (from-to)411
Number of pages1
JournalCancer Prevention Research
Volume15
Issue number6
DOIs
StatePublished - Jun 2022

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Fingerprint

Dive into the research topics of 'Erratum: Pioglitazone, a PPARg Agonist, Suppresses CYP19 Transcription: Evidence for Involvement of 15-Hydroxyprostaglandin Dehydrogenase and BRCA1 (Cancer Prev Res (2012) 5 (1183–1194) DOI: 10.1158/1940-6207.CAPR-12-0201)'. Together they form a unique fingerprint.

Cite this